

Jörn Rosa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1344737/publications.pdf>

Version: 2024-02-01

34
papers

1,523
citations

361296

20
h-index

414303

32
g-index

34
all docs

34
docs citations

34
times ranked

2022
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Aldosteronism and Pregnancy. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 275-285.	0.9	16
2	Blood Pressure Profile, Catecholamine Phenotype, and Target Organ Damage in Pheochromocytoma/Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5170-5180.	1.8	28
3	Catecholamines Induce Left Ventricular Subclinical Systolic Dysfunction: A Speckle-Tracking Echocardiography Study. <i>Cancers</i> , 2019, 11, 318.	1.7	13
4	FGF21 Levels in Pheochromocytoma/Functional Paraganglioma. <i>Cancers</i> , 2019, 11, 485.	1.7	2
5	(Prediction of long-term renal denervation efficacy). <i>Cor Et Vasa</i> , 2019, 61, e378-e384.	0.1	0
6	Blood pressure response to renal denervation is correlated with baseline blood pressure variability. <i>Journal of Hypertension</i> , 2018, 36, 221-229.	0.3	20
7	The revival of catheter-based renal denervation?. <i>Intervencni A Akutni Kardiologie</i> , 2018, 17, 159-163.	0.0	0
8	LONG-TERM EFFECT OF ADRENALECTOMY ON CARDIOVASCULAR REMODELING IN PATIENTS WITH PHEOCHROMOCYTOMA. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2422.	1.8	14
9	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension. <i>Journal of Hypertension</i> , 2017, 35, 1093-1099.	0.3	25
10	Risk Factors for Nonadherence to Antihypertensive Treatment. <i>Hypertension</i> , 2017, 69, 1113-1120.	1.3	150
11	Should All Patients with Resistant Hypertension Receive Spironolactone?. <i>Current Hypertension Reports</i> , 2016, 18, 81.	1.5	6
12	Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. <i>Journal of Human Hypertension</i> , 2016, 30, 35-39.	1.0	19
13	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension. <i>Hypertension</i> , 2016, 67, 397-403.	1.3	73
14	Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness. <i>Journal of Hypertension</i> , 2015, 33, 874-882.	0.3	35
15	Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 1109-1117.	1.0	29
16	The determinants of blood pressure response to exercise. <i>Cor Et Vasa</i> , 2015, 57, e163-e167.	0.1	6
17	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. <i>Blood Pressure</i> , 2015, 24, 263-274.	0.7	65
18	Biochemical Testing After Pheochromocytoma Removal: How Early?. <i>Hormone and Metabolic Research</i> , 2015, 47, 633-636.	0.7	1

#	ARTICLE	IF	CITATIONS
19	Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension. <i>Hypertension</i> , 2015, 65, 407-413.	1.3	178
20	Eligibility for Renal Denervation. <i>Hypertension</i> , 2014, 63, 1319-1325.	1.3	61
21	Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?. <i>Journal of Human Hypertension</i> , 2014, 28, 684-688.	1.0	23
22	Hyperresponders vs. nonresponder patients after renal denervation. <i>Journal of Hypertension</i> , 2014, 32, 2422-2427.	0.3	37
23	Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. <i>European Heart Journal</i> , 2014, 35, 3122-3133.	1.0	249
24	Technical and safety aspects of renal denervation. <i>Cor Et Vasa</i> , 2014, 56, e228-e234.	0.1	5
25	Catheter-based renal denervation versus intensified medical treatment in patients with resistant hypertension: Rationale and design of a multicenter randomized study-PRAGUE-15. <i>Cor Et Vasa</i> , 2014, 56, e235-e239.	0.1	9
26	Changes in Energy Metabolism in Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1651-1658.	1.8	49
27	Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. <i>Journal of Hypertension</i> , 2013, 31, 2455-2461.	0.3	136
28	Vascular Disturbances in Primary Aldosteronism: Clinical Evidence. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 529-533.	0.9	30
29	Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 426-434.	1.0	8
30	Discrepant Results of Adrenal Venous Sampling in Seven Patients with Primary Aldosteronism. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 205-210.	0.9	14
31	Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. <i>Hypertension Research</i> , 2011, 34, 296-300.	1.5	42
32	The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. <i>Journal of Human Hypertension</i> , 2010, 24, 625-630.	1.0	57
33	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. <i>Hypertension Research</i> , 2010, 33, 454-459.	1.5	34
34	Adrenalectomy Improves Arterial Stiffness in Primary Aldosteronism. <i>American Journal of Hypertension</i> , 2008, 21, 1086-1092.	1.0	89